CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AccuStem Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AccuStem Sciences Inc
5 Penn Plaza, 19Th Floor, #1954
Phone: (207) 066-1000p:207 066-1000 NEW YORK, NY  10001  United States Ticker: ACUTACUT
This is a Subsidiary, click here for the Parent Company
Business Summary
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director WendyBlosser 56 3/1/2022 3/1/2022
Chief Financial Officer KeerenShah 46 8/1/2021 8/1/2021
Chief Operating Officer JeffFensterer 43 12/1/2021 12/1/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Accustem Sciences Ltd
ACMSY
ACUT

General Information
Number of Employees: 2 (As of 12/31/2024)
Outstanding Shares: 12,100,535 (As of 3/31/2025)
Shareholders: 510
Stock Exchange: OTC
Fax Number: (302) 387-4000


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025